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Abstract
Variation in plasma levels of cortisol, an essential hormone in the stress response, is associated in population-based studies
with cardio-metabolic, inflammatory and neuro-cognitive traits and diseases. Heritability of plasma cortisol is estimated at
30–60% but no common genetic contribution has been identified. The CORtisol NETwork (CORNET) consortium undertook
genome wide association meta-analysis for plasma cortisol in 12,597 Caucasian participants, replicated in 2,795 participants.
The results indicate that ,1% of variance in plasma cortisol is accounted for by genetic variation in a single region of
chromosome 14. This locus spans SERPINA6, encoding corticosteroid binding globulin (CBG, the major cortisol-binding
protein in plasma), and SERPINA1, encoding a1-antitrypsin (which inhibits cleavage of the reactive centre loop that releases
cortisol from CBG). Three partially independent signals were identified within the region, represented by common SNPs;
detailed biochemical investigation in a nested sub-cohort showed all these SNPs were associated with variation in total
cortisol binding activity in plasma, but some variants influenced total CBG concentrations while the top hit (rs12589136)
influenced the immunoreactivity of the reactive centre loop of CBG. Exome chip and 1000 Genomes imputation analysis of
this locus in the CROATIA-Korcula cohort identified missense mutations in SERPINA6 and SERPINA1 that did not account for
the effects of common variants. These findings reveal a novel common genetic source of variation in binding of cortisol by
CBG, and reinforce the key role of CBG in determining plasma cortisol levels. In turn this genetic variation may contribute to
cortisol-associated degenerative diseases.
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Introduction
The adrenal steroid hormone cortisol plays a vital role in
adaptation to environmental stress. In response to stressors such as
starvation, infection or injury, cortisol secretion is elevated by
activation of the hypothalamic-pituitary-adrenal (HPA) axis.
Cortisol acts predominantly through glucocorticoid receptors to
induce a wide range of physiological responses, including
liberating fuel (by facilitating gluconeogenesis and lipolysis),
maintaining cardiovascular homeostasis (by inducing sodium
retention and vasoconstriction), altering mood and memory (in
favour of focusing on ‘fight or flight’ responses), and acting as a
‘brake’ on the innate immune response (preventing bystander
damage from unrestrained inflammation) [1]. Chronic elevations
in cortisol, however, may be maladaptive, as exemplified in
patients with tumours of the pituitary or adrenal gland causing
Cushing’s syndrome; here, elevated plasma cortisol is responsible
for obesity, type 2 diabetes, hypertension, dyslipidaemia, depres-
sion, memory loss, impaired wound healing, osteoporosis,
myopathy, and many other features.
Epidemiological data suggest that subtle activation of the HPA
axis associates with many of these traits within the population, in
people who do not harbour the tumours which cause overt
Cushing’s syndrome. In these studies higher plasma cortisol
concentration, measured in the morning, provided a robust
marker of the activation of the HPA axis which accompanies
high blood pressure, hyperglycaemia and dyslipidaemia [2–5],
Author Summary
Cortisol is a steroid hormone from the adrenal glands that
is essential in the response to stress. Most cortisol in blood
is bound to corticosteroid binding globulin (CBG). Diseases
causing cortisol deficiency (Addison’s disease) or excess
(Cushing’s syndrome) are life-threatening. Variations in
plasma cortisol have been associated with cardiovascular
and psychiatric diseases and their risk factors. To dissect
the genetic contribution to variation in plasma cortisol, we
formed the CORtisol NETwork (CORNET) consortium and
recruited collaborators with suitable samples from more
than 15,000 people. The results reveal that the major
genetic influence on plasma cortisol is mediated by
variations in the binding capacity of CBG. This is
determined by differences in the circulating concentra-
tions of CBG and also in the immunoreactivity of its
‘reactive centre loop’, potentially influencing not only
binding affinity for cortisol but also the stability of CBG
and hence the tissue delivery of cortisol. These findings
provide the first evidence for a common genetic effect on
levels of this clinically important hormone, suggest that
differences in CBG between individuals are biologically
important, and pave the way for further research to dissect
causality in the associations of plasma cortisol with
common diseases.
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age-associated cognitive dysfunction [6], and low mood [7].
Conversely, lower cortisol associates with immunological abnor-
malities [8], post-traumatic stress disorder (PTSD) [9], and obesity
[1] (the inverse association with obesity is likely due to increased
metabolic clearance of cortisol and confounds the positive
association of cortisol with other cardiovascular risk factors,
explaining some inconsistencies in the associations of cortisol with
‘metabolic syndrome’ [1]). Mechanisms underlying these associ-
ations remain uncertain, with most investigators suggesting
abnormal central control of the HPA axis [1,10,11]. A high
proportion of cortisol in plasma is protein bound, mostly to
corticosteroid binding globulin (CBG). Although variations in total
CBG concentrations have been associated with features of
metabolic syndrome [12,13], this does not account entirely for
associations of total plasma cortisol with other quantitative traits
[5,14,15].
Morning plasma cortisol has a heritability of 30–60% [16–18].
Identifying genetic variants which contribute to variation in
morning cortisol values could provide key insights into the
mechanism of HPA axis activation associated with common
quantitative traits, and an opportunity to dissect causality using
Mendelian randomisation [19]. Attempts to identify these genetic
variants to date have been limited to small candidate gene studies
[18]. We therefore established the CORtisol NETwork (COR-
NET) consortium with the initial aim of identifying genetic
determinants of inter-individual variation in HPA axis function.
Results
Genome-wide association meta-analysis
We conducted a discovery meta-analysis of genome-wide
association studies (GWAMA) of morning plasma cortisol levels,
investigating ,2.5 M SNPs in 12,597 men and women, aged 14–
102 years, of European origin (Table S1 for participant
characteristics). There was very little inflation of test statistics
(lGC= 1.005, Table S2). The 2log10P values by chromosome for
age- and sex-adjusted cortisol z-scores are shown in Figure 1a. A
quantile–quantile plot (Figure 1b) showed marked departure from
the null for SNPs with low P values, listed in Table S3. Analysis of
data for men and women separately showed no sex-specific effects
(data not shown). The results were similar between all multivar-
iable adjusted models, and whether or not time of sampling was
included as a covariate. The results reported are therefore adjusted
only for age and sex.
There was strong evidence for associations between plasma
cortisol and genetic variation found at chromosome 14q32. In an
additive genetic model, the lead SNP rs12589136 reported a per
minor allele effect of 0.10 cortisol z-score (95%CI 0.07,0.13;
P=4.0610212 after genomic control). The effect allele frequency
was 0.22 and this variation explained 0.13% of the morning
plasma cortisol variance. A forest plot showed consistent
directional effects in all studies, with the T allele at rs12589136
associated with higher morning plasma cortisol (Figure 2). Only
minimal heterogeneity was observed between studies (I2 = 0.18).
A recombination boundary containing SERPINA6 and SER-
PINA1 was found to contain all variants at this locus contributing
to association with plasma cortisol (Figure 3). A clumping
procedure [20] identified rs12589136 (4 kb upstream of SER-
PINA6), rs11621961 (1 kb downstream of SERPINA6) and
rs2749527 (30 kb upstream of SERPINA6) as markers representing
genome-wide significant signals in this region. Individually, the
beta (for effect on cortisol z score, 95%CI) for minor (all T) alleles
at rs12589136, rs2749527, and rs11621961 were 0.10 (0.07,0.13;
P=3.3610212), 20.08 (20.11,20.06; P=5.2610211), and 20.08
(20.10,20.05; P=4.061028); joint analysis showed these SNPs
have partially independent effects, with beta (95%CI) 0.07
(0.04,0.10; P=3.161025), 20.04 (20.07,20.01; P=0.012), and
20.03 (20.07,0.00; P=0.037), respectively.
The SERPINA6 gene encodes corticosteroid binding globulin
(CBG). The neighbouring (upstream) gene, SERPINA1, encodes
a1-antitrypsin, the inhibitor of neutrophil elastase which cleaves
and inactivates CBG [21].
Figure 1. Meta-analysis of genome wide association studies for
morning plasma cortisol. A) Manhattan plot of 2lop10P values by
chromosome. The red horizontal line indicates genome-wide signifi-
cance (P,561028) and the blue horizontal line indicates moderate
significance (P,561025). The lead SNP rs12589136 (chr14:94,793,686;
b37) in red is genome-wide significant. SNPs within 650 kb of cortisol-
related candidate genes (listed in Table S6) are highlighted in colours. B)
Quantile-quantile plot of 2log10P, comparing the distribution of
observed 2log10P-values and that expected by chance.
doi:10.1371/journal.pgen.1004474.g001
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Conditional analysis
A quantile-quantile plot after removal of the SERPINA6/
SERPINA1 region (chr14: 94,768,859–94,843,565; Genome Ref-
erence Consortium build 37) showed no evident inflation of test
statistics (not shown). Conditional analyses adjusting for each of
the partially independent genome-wide significant variants
(rs12589136, rs11621961, rs2749527) in a subset of the meta-
analysis population reduced the significance of all other SNPs to
P.161025 for an association with plasma cortisol.
Gene-centric associations
We used a gene-centric approach to analyse the combined effect
of all SNPs within a gene, rather than individual SNP associations,
using VEGAS [22]. This produced a gene-based test statistic from
meta-analysis results, allowing identification of genes containing
multiple SNPs that individually did not reach genome-wide
significance (Table S4). Only SERPINA6 and SERPINA1 were
identified as gene-wide significant (P,361026); both included
rs12589136 in the gene boundary.
Candidate gene analysis
A list of 61 candidate genes thought likely to influence plasma
cortisol was collated by a panel of experts. A Manhattan plot of the
2log10P values highlighted for SNPs in these candidate genes
showed that only SERPINA6 reached genome-wide significance
(Figure 1a). Using gene-based p-values from VEGAS, after
adjusting for multiple testing, only SERPINA6 was associated with
plasma cortisol (Table S5). SERPINA1 was not included in the
candidate gene list.
Replication
In 2,795 participants in additional cohort studies, the associa-
tion with plasma cortisol was replicated for the lead SNP
rs12589136 (P=0.0002), rs11621961 (P=0.003) and rs2749529
(used as proxy for rs2749527, P=0.019)(Table 1; Table S1 for
participant characteristics; Table S6 for results in each cohort).
Functional consequences of genetic variation in the
SERPINA6/SERPINA1 region
We explored the associations between rs12589136, rs11621961,
rs2749527 with cortisol and CBG phenotypes in more detail in
316 subjects from the CROATIA-Korcula cohort (Table 2).
Together these three SNPs explained 0.54% of the variance in
total plasma cortisol in CROATIA-Korcula. However, there were
Figure 2. Forest plot of association of morning plasma cortisol
with rs12589136. Plot shows association as beta values with 95%CI
for morning plasma cortisol z-scores for rs12589136 (T allele) in
discovery cohorts (blue) and meta-analysis (red).
doi:10.1371/journal.pgen.1004474.g002
Figure 3. Regional associations surrounding lead SNP rs12589136 in genome-wide meta-analysis of morning plasma cortisol.
Regional plot shows2log10P values of all SNPs, and degree of correlation between all SNPs and lead SNP rs12589136. SNPs with lower P values span
SERPINA6 and SERPINA1 genes within a recombination boundary.
doi:10.1371/journal.pgen.1004474.g003
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distinct patterns of association of ‘high cortisol’ alleles with CBG.
After adjusting for age and sex, although all three variants were
associated with differences in total cortisol binding activity,
measured by the binding of [3H]-cortisol, there were different
associations with CBG immunoreactivity. The T allele at
rs2749527 was associated with higher ‘total’ CBG concentration
by radioimmunoassay, and there were similar, but weaker
associations of total CBG immunoreactivity with variation at
rs11621961. Differences in calculated free plasma cortisol reflected
these differences in total CBG immunoreactivity, which is used in
the calculation of free cortisol. In contrast, however, the minor (T)
allele at rs12589136 was not associated with ‘total’ CBG
immunoreactivity but was strongly associated with the proportion
of CBG bound by a monoclonal antibody against an epitope in the
reactive centre loop of CBG [23]. None of these SNPs
representing signals in the SERPINA6/SERPINA1 region was
associated with a1-antitrypsin concentrations in blood. However,
a1-antitrypsin levels were negatively correlated with plasma total
cortisol (beta 20.17 (95%CI 20.28, 20.06); P=0.002) and
calculated free cortisol (beta 20.13 (95%CI 20.24, 20.02);
P=0.021), although they did not correlate with ratio of intact/
total CBG 0.02 (95%CI 20.09, 0.13; P=0.715).
We investigated exome chip data for this locus in all
CROATIA-Korcula participants to identify non-synonymous
variants in the SERPINA6/SERPINA1 region associated with
plasma cortisol. From 34 variants on the exome chip in this region
(chr14:94,770,585–94,857,029, build 37), 9 were polymorphic in
this sample (Table S7) but only two were associated with plasma
cortisol: rs113418909 in SERPINA6 (Leu115His in CBG, previously
reported as the Leuven mutation associated with low total cortisol
[24]); and rs28931570 in SERPINA1 (Arg63Cys in a1-antitrypsin,
not recognised as a disease-causing variant [25]). We also analysed
735 additional SNPs in the same region imputed from 1000
Genomes data in all CROATIA-Korcula participants but did not
find any additional SNPs associated with plasma cortisol, using a P
threshold of 0.05/735= 761025. The two rare variants
rs113418909 and rs28931570 were in perfect linkage disequilib-
rium amongst participants with detailed biochemical phenotyping
performed, so results are reported for rs113418909 only (Table 2).
Prevalence of the Leuven variant in CROATIA-Korcula was
higher than expected (MAF=0.017, compared with
MAF=0.0046 in dbSNP). After adjusting for age, sex, and
accounting for kinship, participants who were heterozygote for the
Leuven variant had lower total cortisol and markedly lower total
cortisol binding activity, but normal CBG immunoreactivity
(Table 2).
After removing subjects with the rare Leuven variant (ie.
heterozygotes), rs12589136 remained associated with total cortisol
(0.15, 95%CI 0.04,0.26; P=0.009), calculated free cortisol (0.17,
95%CI 0.02,0.32; P=0.031), and the proportion of CBG bound
by the reactive centre loop antibody (20.45, 95%CI 20.60,2
0.29; P=2.861028).
Discussion
These results clearly attribute inter-individual differences in
morning plasma cortisol amongst Europeans to genetic variation
within a region on chromosome 14 containing the SERPINA6 and
SERPINA1 genes. The association of this region with plasma
cortisol was consistent across multiple cohorts and was observed
not only in genome-wide meta-analysis of individual SNPs, but
also in gene-based hypothesis-free analysis, and in a candidate
gene analysis. Investigation of the functional consequences of
genetic variation in this region in a genetic isolate population in
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Croatia indicates that the effects of variation at SERPINA6 and
SERPINA1 on plasma cortisol are likely to be mediated through
alterations in total cortisol binding by corticosteroid binding
globulin (CBG). In part, this is determined by differences in total
CBG concentrations, and in part in association with a previously
unrecognised variability in the immunoreactivity of the reactive
centre loop of CBG. Since the process of CBG cleavage by
neutrophil elastase and resultant reconfiguration of the reactive
centre loop is considered important in the release of bioavailable
cortisol within target tissues [21,26], this finding provides a novel
insight into a biological pathway controlling cortisol action.
The diverse actions of cortisol, and the striking clinical
consequences of glucocorticoid excess or deficiency, have led
many investigators to propose a central role for variations in
cortisol levels in determining common quantitative traits. Howev-
er, cortisol has not been measured as widely in epidemiological
Table 2. Functional consequences of variants in the SERPINA6/A1 locus significantly associated with morning plasma cortisol in
GWAMA, and of the Leuven variant, in CROATIA-Korcula.
rs11621961 Beta (95%CI) Pc
TT CT CC
Total cortisola 655 (618,694) [129] 664 (644,685)[411] 675 (654,696)[357] 20.05 (20.14,0.05) 0.305
Calculated free cortisol 42 (35.0,51)[56] 47 (42,52)[126] 50 (46,55)[136] 20.14 (20.28,0.00) 0.049
Measured free cortisolb 14 (11,17)[27] 14 (11,16)[70] 13 (10,16)[67] 0.01 (20.2,0.22) 0.933
Total CBG 0.90 (0.82,0.99)[56] 0.90 (0.85,0.94)[126] 0.96 (0.92,1.01)[136] 20.12 (20.26,0.02) 0.103
RCL/total CBG 0.76 (0.71,0.80)[56] 0.77 (0.74,0.79)[125] 0.76 (0.73,0.78)[136] 0.01 (20.14,0.15) 0.940
Cortisol binding activity 503 (473,532)[56] 492 (474,511)[125] 531 (512,550)[136] 20.17 (20.32,20.03) 0.016
a1-antitrypsin 2.74 (2.37,3.16)[56] 2.74 (2.51,2.99)[124] 2.66 (2.43,2.91)[134] 0.02 (20.14,0.17) 0.840
rs12589136
TT GT GG
Total cortisola 706 (656,760)[53] 681 (657,706)[302] 655 (638,673)[540] 0.13 (0.02,0.24) 0.017
Calculated free cortisol 47 (41,54)[52] 54 (45,65)[47] 46 (42,50)[217] 0.13 (20.01,0.26) 0.073
Measured free cortisolb 13 (11,16)[39] n/a 13 (12,15)[125] 0.03 (20.15,0.2) 0.777
Total CBG 1.01 (0.95,1.07)[52] 0.91 (0.82,1.02)[47] 0.91 (0.87,0.95)[217] 0.06 (20.07,0.20) 0.371
RCL/total CBG 0.68 (0.64,0.71)[52] 0.69 (0.65,0.73)[47] 0.80 (0.78,0.82)[216] 20.49 (20.64,20.34) 9.4610211
Cortisol binding activity 557 (532,581)[52] 552 (513,591)[47] 491 (477,505)[216] 0.30 (0.16,0.44) 2.361025
a1-antitrypsin 2.68 (2.36,3.05)[51] 2.77 (2.43,3.16)[47] 2.69 (2.50,2.90)[214] 0.06 (20.09,0.22) 0.421
rs2749527
CC CT TT
Total cortisola 659 (635,684)[251] 668 (649,687)[431] 674 (643,707)[212] 0.03 (20.06,0.12) 0.495
Calculated free cortisol 49 (43,55)[102] 45 (41,50)[123] 48 (42,55)[92] 0.02 (20.11,0.16) 0.717
Measured free cortisolb 16 (14,19)[60] 11 (8,15)[51] 13 (11,15)[53] 20.11 (20.29,0.07) 0.246
Total CBG 0.87 (0.82,0.92)[102] 0.92 (0.87,0.98)[123] 1.00 (0.96,1.05)[92] 0.17 (0.03,0.30) 0.014
RCL/total CBG 0.76 (0.73,0.79)[102] 0.76 (0.74,0.79)[122] 0.76 (0.73,0.79)[92] 20.02 (20.16,0.13) 0.824
Cortisol binding activity 486 (468,504)[102] 507 (486,528)[122] 545 (524,566)[92] 0.24 (0.11,0.38) 4.361024
a1-antitrypsin 2.58 (2.31,2.88)[101] 2.86 (2.62,3.12)[121] 2.65 (2.38,2.94)[91] 0.08 (20.06,0.23) 0.268
rs113418909 (Leuven)
AA AT
Total cortisol 673 (658,688)[792] 562 (500,631)[28] 20.63 (21.01,20.25) 0.001
Calculated free cortisol 48 (45,52)[280] 38 (27,52)[9] 20.43 (21.06,0.20) 0.182
Measured free cortisol 14 (12,15)[147] 13 (8,20)[5] 20.04 (20.92,0.83) 0.924
Total CBG 0.93 (0.90,0.96)[280] 0.94 (0.82,1.07)[9] 0.05 (20.58,0.68) 0.870
RCL/total CBG 0.76 (0.74,0.78)[279] 0.82 (0.78,0.87)[9] 0.51 (20.18,1.19) 0.146
Cortisol binding activity 512 (500,524)[279] 347 (305,389)[9] 21.54 (22.17,20.91) 1.961026
a1-antitrypsin 2.67 (2.51,2.84)[277] 2.40 (1.91,3.03)[9] 20.12 (20.83,0.58) 0.732
aData for total cortisol is from the whole Croatia-Korcula sample, n = 898.
bSamples selected for measured free cortisol assay were age and sex matched homozygotes at rs12589136.
cadjusted for age, sex, and first three principal components, using kinship matrix derived from GWAS data.
Data are geometric mean (95% CI)[n]. Cortisol values are nmol/L, CBG mmol/L, cortisol binding activity nmol/L, and a1-antitrypsin g/L. RCL = reactive centre loop.
doi:10.1371/journal.pgen.1004474.t002
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cohort studies as many other phenotypes. This may reflect the
perceived difficulty of obtaining samples at a fixed time of day and
in un-stressed conditions, to avoid confounding effects. The
CORNET consortium had to decline samples from many cohorts
in which time of sampling was inadequately controlled, and even
then there was high variability in plasma cortisol. Thus, although
the variants we identified in the SERPINA6/SERPINA1 region of
chromosome 14 accounted for ,1% of the variance in plasma
cortisol, this signal may be obscured by substantial unmeasured
confounding and measurement error and may comprise a
considerable component of the estimated 30–60% heritability of
plasma cortisol [16–18]. We identified 3 SNPs with partially
independent effects on plasma cortisol. There may be a small
degree of linkage disequilibrium between these SNPs, but they also
show different associations with CBG biochemistry, suggesting
that they represent independent effects. None of these 3 SNPs
appears directly to affect CBG function; although rs12589136 is
close to a consensus estrogen response element, there was no
gender difference in its association with plasma cortisol.
Previous investigations of the genetic determinants of plasma
cortisol (reviewed in [18]) have been underpowered candidate
gene studies, including some which included a tandem repeat in
intron 1 of SERPINA6 [27,28]. Interestingly, many of the genetic
variants previously associated with cortisol, eg for glucocorticoid
[1] and mineralocorticoid [29,30] receptors, showed no signal
whatsoever in the adequately powered GWAMA and candidate
gene analysis conducted here.
Rare mutations in SERPINA6 have been described which cause
absent CBG protein or, more often, reduced affinity of CBG for
cortisol [31–35]. Affected individuals have low total plasma
cortisol but normal free plasma cortisol. However, they also have
abnormal pulsatility of plasma cortisol, and non-specific symptoms
including fatigue which are unresponsive to cortisol supplemen-
tation; features which have been attributed to abnormal function
of CBG in delivering cortisol to target tissues, including in brain
regions involved in negative feedback regulation of the HPA axis
[21]. Although one of these mutations, A51V, has been found to
be surprisingly prevalent (MAF.3%) amongst Chinese subjects
[34], it has not been found in non-Asian populations and we did
not find Caucasians carrying this mutation when tested by exome
chip analysis. In cohort studies, plasma CBG concentrations have
been associated with features of the metabolic syndrome
[12,13,15] and one previous candidate gene study with .900
participants showed that SNPs in SERPINA6, including some
identified as being associated with plasma cortisol in this
GWAMA, were predictive of somatic symptoms [36]. We found
evidence that genetic variation in the SERPINA6/SERPINA1
region influences total plasma cortisol not only through changes in
total CBG concentrations, but also in association with alterations
in the immunoreactivity of the reactive centre loop of the CBG
protein.
Cleavage of the reactive centre loop (RCL) of CBG by
neutrophil elastase and inhibition of elastase activity by a1-
antitrypsin has been recognised for more than 20 years [26].
However, the recent development of monoclonal antibodies which
recognise the intact RCL of CBG has allowed this process to be
studied in vivo for the first time [23]. Using these tools in samples
from Croatia-Korcula has provided the novel insight that
immunoreactivity of the RCL of CBG is variable in the
population, and further that this is explained in part by genetic
variations in the SERPINA6/SERPINA1 region. It remains to be
determined whether this difference in immunoreactivity of the
RCL represents altered susceptibility to CBG cleavage. We show
that a common variant (rs12589136) associated with impaired
RCL antibody binding was associated with higher total plasma
cortisol and higher cortisol binding activity. These observations
are inconsistent with the interpretation that impaired RCL
antibody binding represents enhanced RCL cleavage [23], given
that cleaved CBG has a lower affinity than intact CBG for cortisol
binding [37]. Alternatively, the altered immunoreactivity of the
RCL epitope may represent resistance to cleavage and hence
enhanced cortisol binding. It is possible that the genetically
determined difference in the RCL epitope of CBG is associated
with impaired negative feedback of the HPA axis due to reduced
tissue delivery of cortisol by CBG, analogous with findings in CBG
knockout mice [38]. Although we could not confirm associated
elevation in free plasma cortisol concentrations, these measure-
ments are notoriously unreliable, for example being similarly
unhelpful in dissecting the consequences of CBG deficiency
described above.
We found further evidence for the importance of CBG using
exome chips in the genetic isolate population of Korcula in
Croatia, where we discovered an unusually high prevalence of
heterozygotes for the Leuven mutation in SERPINA6 [24]. These
individuals have lower total plasma cortisol despite normal total
CBG concentrations, and we confirmed substantial reductions in
total cortisol binding activity, without any difference in RCL
antibody binding. The presence of the Leuven variant, however,
did not account for the association of the top hit SNPs identified
by GWAMA with plasma cortisol or CBG RCL antibody binding.
It is possible that a combination of alterations in CBG substrate
as well as in neutrophil elastase level and/or activity may
determine cleavage of CBG and tissue delivery of cortisol,
especially in local sites of inflammation [21]. Intriguingly, we
found inverse associations between levels of a1-antitrypsin, the
inhibitor of neutrophil elastase, and plasma cortisol concentra-
tions, consistent with instability of CBG resulting in HPA axis
activation as proposed above; however, we could not identify a
genetic influence on this relationship, or confirm its association
with CBG RCL immunoreactivity. Specifically, we did not identify
independent signals for SERPINA6 and SERPINA1 in conditional
analysis, and the rare variant Leuven mutation was in linkage
disequilibrium with the only rare variant we identified in
SERPINA1. Recent studies have identified variants in SERPINA1
that are associated with coronary artery calcification [39] and
serum lipid profile [40], the latter represented by rs1303 which is
in linkage disequilibrium with the top hit rs12589136 identified by
GWAMA (r2 = 0.35). These findings are consistent with variation
in the SERPINA6/SERPINA1 locus affecting downstream actions
of cortisol, but it remains unclear if an interaction exists between
the variants at these two genes. Mutations in SERPINA1 cause the
syndrome of a1-antitrypsin deficiency, but we are not aware of any
investigations of CBG or cortisol in these patients, and their HPA
axis may be disturbed anyway by un-restrained neutrophil-
mediated tissue damage. Rare variants in SERPINA1 (notably
rs112635299) have been associated with a1-globulin plasma
protein levels, of which a1-antitrypsin is a major constituent,
using GWAS with 1000 Genomes imputation [41]. However, in
the CROATIA-Korcula cohort neither rs1303 (Table S7) nor
SNPs imputed from 1000 Genomes (including rs112635299) were
associated with plasma cortisol. More detailed phenotyping
amongst participants with contrasting genotypes at the SER-
PINA6/SERPINA1 region will be required to clarify the basis for
altered interaction between the two gene products.
These findings emphasise the biological importance of plasma
protein binding for steroid hormones, and are analogous to recent
findings that a common variant in sex hormone binding globulin
contributes to variation in total testosterone levels [42]. Given the
Genome Wide Association Studies of Plasma Cortisol
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consequences of altered binding protein function for steroid
volume of distribution and clearance, and documented effects on
HPA axis function [21], this is an important finding of itself.
However, potentially of greater importance is the novel observa-
tion that a key protein domain of CBG, the reactive centre loop, is
subject to inter-individual differences which are influenced by
genetic variation and may constitute a novel influence on tissue
steroid action.
Materials and Methods
Gene discovery
We performed a meta-analysis of genome-wide association
studies of morning plasma cortisol in 12,597 subjects from 11
western European population-based cohorts: CROATIA-Vis
(n = 885), CROATIA-Korcula (n = 898), CROATIA-Split
(n = 493), ORCADES (n= 886), Rotterdam Study (n= 2945),
NFBC1966 (n = 1195), Helsinki Birth Cohort Study 1934–44
(n = 451), ALSPAC (n= 1567), InChianti (n = 1207), PREVEND
(n=1151), and PIVUS (n= 919). Replication was tested in 2,795
subjects from three independent cohorts: Raine Study (n= 797),
ET2DS (n= 1,069), and MrOS-Sweden (n = 929). Cortisol was
measured by immunoassay in blood samples collected from study
participants between 0700 and 1100 h. Inclusion criteria were
adults aged 17 years or older from Caucasian populations;
exclusion criteria were current glucocorticoid use, pregnant or
breast feeding women, and twins (exclusion of one). Characteristics
of the study populations are presented in Table S1 and details of
each cohort are provided in Text S1. All participants provided
written informed consent and studies were approved by local
Research Ethics Committees and/or Institutional Review Boards.
Association analysis with morning plasma
cortisol. Each study performed single marker association tests,
and study-specific linear regression models which used z-scores of
log-transformed cortisol, additive SNP effects, and were adjusted
for age and sex (model 1); age, sex, and smoking (model 2); or age,
sex, smoking and body mass index (model 3). Imputation of the
gene-chip results used the HapMap CEU population, build 36. In
cohorts with consanguineous populations (ORCADES and
Croatia), adjustments for principal components in kinship matrices
were performed using ProbABEL; for other cohorts, Identity-By-
Descent coefficients were calculated using PLINK and related
participants excluded. In the majority of cohorts, participants were
only included if blood samples had been obtained within a
60 minute time interval, when variations in time of sampling were
ignored. In a subset of cohorts, samples were obtained over a
wider time interval (but always in the morning before 1100 h) and
time of blood sampling recorded; for these cohorts, three further
models were run as above but also including time of sampling,
calculated as minutes from first sampling time, as an additional
covariate [43].
Quality control was carried out on the imputed genome-wide
data for all 11 studies prior to meta-analysis; this excluded all
samples with a minor allele frequency (MAF) ,2%, call rate ,
95%, Hardy-Weinberg equilibrium (HWE),161028 and poor
imputation quality (MACH R2_HAT,0.30, IMPUTE PROP-
ER_INFO,0.60, BEAGLE INFO,0.30, as appropriate). Quan-
tile-quantile (QQ) plots and genomic control (lambda) were used
to confirm quality control. Sex chromosomes were not analysed.
Meta-analysis of association results. We performed fixed
effects meta-analysis, which used combined allelic effects weighted
by the inverse of their variance for each of the models using the
GWAMA program [44]. This aligned all studies to the same
reference allele at each SNP, thus avoiding strand errors, and
excluded SNPs with obvious input errors (eg. discrepancies in
effect allele frequencies). The results from analysis with or without
genomic control were nearly identical, as expected with
lGC= 1.005. The genome-wide significance threshold for the
meta-analysis was P,561028. Percentage variation of cortisol was
calculated from meta-analysis results as (2*effect allele frequen-
cy)*(1-effect allele frequency)*(beta2/sd2). A regional plot was
generated using LocusZoom [45], and heat map using snp.plotter
[46] in R version 2.15.2. Joint analysis of meta-analysis was
performed with the GCTA program [47].
Clumping analysis. To detect independent top SNPs on the
basis of empirical estimates of linkage disequilibrium between the
SNPs, we used the clumping function as implemented in PLINK
[20]. All the SNPs with a P-value,561025 in meta-analysis were
used for clumping. We grouped the SNPs within 500 kb of the
index SNP that have r2 .0.2 with the index SNP.
Replication genotyping and analysis. Genes identified in
the meta-analysis were evaluated in the Raine Study, MrOS-
Sweden, and Edinburgh type 2 Diabetes Study (ET2DS).
Raine Study and MrOS-Sweden had GWAS data so we
extracted the replication SNP results, and ET2DS was
genotyped at the Wellcome Trust Clinical Research Facility
Genetics Core Laboratory in Edinburgh using the OpenArray
genotyping platform. rs2749527 failed manufacture for the
OpenArray, and was replaced with rs2749529 (r2 = 0.905,
D9= 1.0) in all replication cohorts. Genotypic association
analysis in these studies followed the same methods as those
described above for the discovery meta-analysis, adjusting for
age and sex.
Conditional & sex-specific analysis. We performed meta-
analyses of sex-specific GWAS and conditional GWAS in a subset
of populations, using single marker association tests of z-scores of
log-transformed cortisol. For the sex-specific analysis, each study
adjusted for age in both men (n = 3,546) and women (n = 5,956).
For the conditional analysis, each study adjusted for age, sex, and
each of the SERPINA6 loci SNPs rs12589136 (n = 9,308),
rs11621961 (n= 7,687), and rs2749527 (n= 9,307) individually.
We then did fixed effects meta-analysis using GWAMA program.
Gene-based analysis. We used the Versatile Gene-based
Association Study (VEGAS) program [22] to perform gene-
centric analysis. This used individual SNP p-values derived
from the meta-analysis results to compute a gene-based p-
value. We used two methods: all SNPs within a gene, or a
subset of the 10% most significant SNPs in each gene
boundary. VEGAS accounted for linkage disequilibrium
between SNPs using the HapMap phase 2 population (CEU).
SNPs were assigned to ,18,000 genes based on positions in
build 36 (hg18), with gene boundaries of 650 kb of the UTR.
Bonferroni corrected threshold for gene-wide significance was
361026. The overlap of SNPs included in the gene boundaries
in our results indicates this is likely to be an overly conservative
correction factor [22].
A list of 61 candidate genes with known biological function in
the regulation of cortisol was compiled by a panel of experts in the
field. All SNPs within and 650 kb of these genes were examined
in the GWAMA results, and gene-based p values were inspected in
VEGAS results.
Exome chip and 1000 Genomes imputed data analysis
Genotypes for the SERPINA6/SERPINA1 gene region
(chr14:94,770,585–94,857,029, build 37) in the CROATIA-
Korcula samples (n = 898) were extracted from an Illumina
Exome Chip v1 analysis. Genotypes were called in GenomeStudio
(Illumina) using the CHARGE Consortium joint calling cluster file
Genome Wide Association Studies of Plasma Cortisol
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(http://www.chargeconsortium.com/main/exomechip) [48].
1000 Genomes imputation was performed using genotypes from
Illumina HumanHap370CNV after quality control (Individual
Call Rate 97%, SNP Call Rate 98%, MAF 0.01, HWE 161026);
prephasing was performed using ShapeIt v2 [49] and imputation
using IMPUTE2 [50] and the ALL (Phase 1 integrated release v3,
April 2012) reference panel. Associations with plasma cortisol were
analysed in GenABEL [51].
Detailed biochemical studies
More detailed phenotyping was undertaken in samples from
316 participants in the CROATIA-Korcula cohort, comprising
158 age- and sex-matched homozygotes at the top hit variant
rs12589136 (53 T/T, 106 G/G; however, one T/T sample
had insufficient sample for CBG measurement resulting in 52
T/T and 106 G/G). An additional 160 randomly selected
samples had CBG measured, however two samples failed
genotyping resulting in an additional 47 T/G and 111
G/G.
Total plasma cortisol was measured with a commercial
radioimmunoassay (MP Biomedicals, UK). Total CBG was also
measured in CROATIA-Korcula samples using a commercial
radioimmunoassay (DiaSource, Louvain-la-Neuve, Belgium). To-
tal cortisol binding capacity was measured using a ligand-
saturation assay, with [3H]-cortisol (PerkinElmer Life Sciences,
Waltham, MA) as the labelled ligand and dextran-coated charcoal
to separate the CBG-bound [3H]cortisol, as previously described
[52]. a1-Antitrypsin was measured with a commercial ELISA
(Genway Biotech, San Diego, USA). Unbound free plasma cortisol
was calculated from measured total plasma cortisol and total CBG
values using Coolens’ equation [53]. Free cortisol was also
measured by ELISA following equilibrium dialysis. Briefly, dialysis
tubing (12–14 kD, Medicell, London, UK) was heated to 80C
for 30 min in 2% Na bicarbonate and 1 mM EDTA before
overnight dialysis of plasma into phosphate buffered saline
containing 1% gelatin at 37C and measurement of dialysed free
cortisol by commercial ELISA (Salimetrics Europe Ltd, New-
market, UK). CBG were also measured, as previously described
[23], by ELISAs using monoclonal antibodies 12G2 and 9G12.
Antibody 9G12 binds to an epitope in the reactive centre loop
(RCL), the elastase cleavage site on CBG, and has been used to
infer intact (uncleaved) CBG, whereas antibody 12G2 binds to a
distant epitope and measures total (cleaved and uncleaved)
CBG.
As CROATIA-Korcula is a population isolate, we used the
polygenic and mmscore functions in GenABEL [51]. All
regression equations included the first three principal components
and kinship matrix derived from GWAS data in this population
and used z-scores of the traits. All variables were normalised
using log transformation (cortisol, calculated free cortisol,
measured free cortisol, CBG, a1-antitrypsin), and reported
means are geometric means, the ratio of intact/cleaved was
normally distributed.
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